top of page
Lab Worker


Real-time monitoring and characterization of biomolecular interactions


Biosensing implicates numerous challenges, ranging from the accurate quantification of proteins, characterizing kinetic parameters of biomolecular interactions within complex matrices and in different environmental conditions. crucial for understanding physiological processes, to monitoring real-time molecular interactions amidst the diverse array of biomolecules present in complex media.


At Affinite Instruments, our innovative solutions tackle diverse biosensing challenges, empowering researchers to accurately quantify proteins, analyze kinetic parameters of biomolecular interactions within complex matrices, and monitor real-time molecular interactions in various environments. By enabling efficient and effective biosensing, we pave the way for transformative discoveries in healthcare, biotechnology, and beyond.

P4SPR 2.0 Profile.png
PRO Profile.png
Affipump Profile.png
PRO Profile.png

Compatible Targets


Real-World Application

Evaluating kinetic parameters 

Evaluating kinetic parameters using SPR, including kon, koff and KD is crucial in biosensing. These parameters offer insights into the strength and specificity of molecular interactions, allowing precise characterization of binding events in real-time. Moreover, SPR-generated data is seamlessly compatible with TraceDrawer, facilitating comprehensive analysis and visualization. Additionally, SPR software often allows effortless data export to other platforms, enhancing flexibility and interoperability in data analysis workflows.


Quantification of proteins

The P4 series streamlines protein quantification and activity monitoring with precision and reproducibility. The automated data analysis tools in our ezControl software facilitates dynamic profiling and accurate quantification of protein activity, enhancing research efficiency and insights saving both time and resources for subsequent experiments.

Analysis in complex media

Affinite Instruments collaborated with researchers and agencies to develop assays informing immune response to SARS-CoV-2 and vaccine development. During this project, scientists validated our SPR against ELISA in complex media such as plasma, serum, and dry blood spots. Notably, a pseudo-neutralization assay was validated to evaluate the humoral response to SARS-CoV-2 in clinical serum samples, greatly advancing our understanding of the virus's immune response and vaccine effectiveness.

Blood Sample
Bioanalytical Cancer therapeutic

Methotrexate (MTX) is one of the most widely studied and effective therapeutics agents available to treat many solid tumors, hematologic malignancies, and autoimmune diseases such as rheumatoid arthritis; however, the poor pharmacokinetic and narrow safety margin of the drug limits the therapeutic outcomes of conventional drug delivery systems.​MTX concentrations in a patient’s serum undergoing chemotherapy treatments can be determined by surface plasmon resonance (SPR) sensing using folic acid-functionalized gold nanoparticles (FA-AuNP) in competition with MTX for the bioreceptor, human dihydrofolate reductase (hDHFR) immobilized on the SPR sensor chip.

Bioanalytical Protein-Protein Detection

E. coli L-asparaginase II (EcAII) is a critical component of chemotherapy for childhood acute lymphoblastic leukemia (ALL). This therapeutic, listed as essential medicine by the WHO since 1995, may be compromised by allergic reactions, overt or silent. The main concern relative to the silent hypersensitivity that occurs in 5-46% of patients is the development of neutralizing antibodies that result in silent inactivation of the treatment. In order to monitor the efficacy of the treatment with EcAII, a test to detect the anti-EcAII antibodies (neutralizing antibodies) using the P4SPR. SPR bioassays were performed in undiluted serum from children undergoing therapy for ALL.

Bioanalytical Protein detection
Bioanalytical Protein detection

Breast Cancer Biomarker Detection

Approximately one in five women diagnosed with breast cancer worldwide will have HER2-positive breast cancer, a particularly aggressive form of the disease. Although four diagnostic tests exist, research has shown that some HER2 status test results may still be wrong. ​A diagnostic test using SPR may help address some of the current issues. The potential biosensing application of a new ultra-low fouling ionic liquid is demonstrated using the P4SPR for the analysis of HER2 in breast cancer cell lysates. 

Application Notes

Untitled (5).png

Application note #6

Screening protein-protein interactions


Application note #5

Rapid quality control of antibodies

App note 1 web.png

Application note #1

Gene regulation, DNA-protein binding

bottom of page